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Patient and Public Involvement (within the methods section but repeated here) 
This preliminary research focuses on potential interventions to healthcare teams rather than 
directly to patients. Patient research partners are key members of the overarching project 
team developing implementation methods to aid treat-to-target in PsA. In addition, clinicians 
without an academic interest in PsA were involved in the design of this study, revised draft 
survey questions and contributed to the interpretation of results. Patient research partners 
and non-specialist clinicians continue to contribute to the overarching project committee and 
the data reported here will be used to inform the design of future interventional studies. 
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Key messages 
What is already known about this subject? 
 T2T in PsA is evidence based and recommended in European guidelines, but 
currently not widely implemented 
What does this study add? 
 This study identifies the individual, team and organisational reasons why clinicians do 
not use a T2T approach in PsA 
 This study provides evidence of support and resources that could be utilised to 
support clinicians to use T2T in practice 
How might this impact on clinical practice or future developments? 
 These findings can be mapped onto a behaviour change framework to inform an 
implementation strategy to increase T2T in PsA in practice 
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Objectives 
In treat to target (T2T), the patient is treated to reach and maintain specified and sequentially 
measured goals, such as remission or low disease activity. T2T in psoriatic arthritis (PsA) 
has demonstrated improved clinical and patient reported outcomes and is recommended in 
European guidelines. However, most clinicians do not use T2T in PsA. This study examined 
the barriers and enablers to implementation in practice.  
Methods 
Sequential mixed methods comprising a qualitative design (interviews and focus group) to 
inform a quantitative design (survey). Qualitative data were analysed thematically, and 
quantitative statistics were analysed descriptively.  
Results 
Nineteen rheumatology clinicians participated in telephone interviews or a face-to-face focus 
group. An overarching theme „Complexity‟ (including „PsA versus Rheumatoid Arthritis‟, 
„‟Measurement, and „Resources‟) and an underpinning theme „Changes to current practice‟ 
(including „Reluctance due to organisational factors‟ and „Individual determination to make 
changes‟) were identified.  
153 rheumatology clinicians responded to an on-line survey. Barriers included limited clinic 
appointment time to collect outcome data (54.5%) and lack of training in assessing skin 
disease (35%). Enablers included provision of a protocol (86.4%), a local implementation 
lead (80.9%), support in clinic to measure outcomes (83.3%) and training in T2T (69.8%). 
The importance of regular audit with feedback, specialist PsA clinics, and a web-based 
electronic database linked to hospital/national IT systems were also identified as enablers. 
Conclusions 
Implementation of T2T in PsA requires an integrated approach to address the support, 
training and resource needs of individual clinicians, rheumatology teams, local IT systems, 
and service providers to maximise success.   
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Treat to target (T2T) is a strategy in which clinicians monitor and treat patients to reach and 
maintain explicitly specified and sequentially measured goals, such as remission or low 
disease activity1. The concept was developed for chronic diseases, such as diabetes 
mellitus and hypertension and resulted in improved clinical outcomes 2-4. Recently, we have 
seen a similar paradigm shift in rheumatology 5-7, with the adoption of a T2T approach in 
rheumatoid arthritis (RA) revolutionising patient outcomes 5.  
 
The TIght COntrol of PsA (TICOPA) trial demonstrated improved clinical and patient 
reported outcomes with a T2T approach in psoriatic arthritis (PsA) aiming for the minimal 
disease activity (MDA) criteria8.  This led to the 2015 European League Against Rheumatism 
(EULAR) PsA treatment recommendations that “treatment should be aimed at reaching the 
target of remission or, alternatively, minimal/low disease activity, by regular monitoring and 
appropriate adjustment of therapy”9.  As in other inflammatory arthritides, remission is the 
ultimate therapeutic goal in PsA and should be characterised by “a complete absence of 
disease activity, with no signs or symptoms of active disease”10. However, remission can be 
difficult to achieve and maintain and mild disease activity in one domain may be acceptable.   
 
Despite the trial evidence 8 and EULAR recommendations 9, T2T has not been widely 
implemented. Known concerns include feasibility and cost-effectiveness,11 but we do not 
have a comprehensive understanding of the barriers to this approach. A 2015 UK physician 
survey estimated that around 90% of clinicians do not use a T2T approach (unpublished 
data) or routinely include specific assessments; however, some rheumatology teams have 
successfully implemented T2T. Outcomes can be assessed in 5-10 minutes, initially every 
three months but less frequently as disease control is achieved. Beyond evidence of efficacy 
and effectiveness, research is required to establish the barriers to T2T in practice and 
potential facilitators to overcome them. The long-term aim is to work with stakeholders, 
including clinical teams, healthcare service providers and rheumatology patients, to 
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implement T2T in practice. The aim of the current study was to understand clinicians‟ views 
on implementation of a T2T approach in PsA.  
 
Methods  
A mixed methods sequential exploratory design was used 12 13 comprising a qualitative 
phase followed by a quantitative phase. Qualitative data were collected through interviews 
and a focus group to provide evidence of clinicians‟ views of factors influencing 
implementation of a T2T approach. Statements for inclusion in the quantitative phase were 
generated based on the qualitative analysis, and their comparative importance for 
implementation was examined using an on-line survey. The design rationale is that the 
qualitative phase provided wide-ranging, in-depth data from a smaller sample 14 and the 
quantitative phase provided information on generalisability and relative importance from a 
larger sample. The study findings are presented in line with the reporting standards for 
mixed methods research 15. The study was approved by the Health and Applied Sciences 
Faculty Research Ethics Committee at the University of the West of England, Bristol 
(reference: HAS.18.11.056). 
 
The qualitative phase aimed to understand clinicians‟ interpretations and experiences of T2T 
and to generate evidence on barriers and enablers. A maximum variation sampling strategy 
was selected to include participants with a range of clinical roles and level of rheumatology 
experience, to capture diverse and common perspectives 16. Data were collected in two 
stages: 
1. Individual telephone interviews guided by a schedule developed by the research 
team (Table 1).  
2. A focus group discussion guided by the interview findings (Table 2) to explore areas 
of agreement and/or disagreement with a different sample of rheumatology clinicians.  
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The online survey examined the comparative importance of interview and focus group data 
in a larger sample of clinicians. The survey was created by LC and ED, reviewed by co-
authors, and administered using SurveyMonkey software. It was designed to be brief and 
easy to complete to address the challenge of low response rates among physicians17. There 
were 37 survey statements with five-point Likert response options and three questions 
related to demographics (professional background, years in practice, and country of 
practice). The statements were divided into four sections: clinician opinions; practical factors; 
enabling factors; and behavioural framework items (see Supplementary Materials).18 The 
data on behavioural framework items were collected to support the design of a future 
implementation study and will not be reported here. 
 
Patient and Public Involvement 
This preliminary research focuses on potential interventions to healthcare teams rather than 
directly to patients. Patient research partners are key members of the overarching project 
team developing implementation methods to aid treat-to-target in PsA. In addition, clinicians 
without an academic interest in PsA were involved in the design of this study, revised draft 
survey questions and contributed to the interpretation of results. Patient research partners 
and non-specialist clinicians continue to contribute to the overarching project committee and 
the data reported here will be used to inform the design of future interventional studies. 
 
Recruitment and data collection  
Qualitative phase 
Participants were recruited via The British Psoriatic Arthritis Consortium (BritPACT) network, 
a multi-disciplinary consortium of clinicians and researchers in the UK with an interest in 
PsA. For the interviews, study packs comprising a cover letter and Participant Information 
Sheet (PIS) were emailed to approximately 80 rheumatology clinicians. Approximately four 
months later, information about the focus groups was sent to the same mailing list with a 
new cover letter and PIS, but participants from the interviews were not permitted to 
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participate. Telephone interviews were conducted by JT, a rheumatology nurse specialist. 
The focus group was organised by LC (a rheumatology consultant), and facilitated by JT, 
with ED (a psychologist) notetaking to aid transcription. The interviews and focus group were 
audio-recorded, transcribed verbatim, checked for accuracy against the audio-recordings, 
and anonymised by removing the names of people and places. Interview data were analysed 
manually using an inductive thematic approach 19. This involved coding chunks of data, then 
grouping clusters of related codes to form themes. It was a data-driven approach, with no a 
priori theory informing the identification of codes. JT analysed all interview transcripts and 
ED independently analysed two transcripts.  The themes identified at this stage informed the 
topic guide for the focus group discussion (Table 2). The focus group data were analysed by 
JT and ED manually, using a deductive thematic approach guided by the interview 
findings.20 No new themes were identified and so the findings are presented as a single 
analysis based on the interview and focus group data sets. Themes are evidenced by data 
excerpts from participants and identified by INT (interview) or FG (focus group) and a 
participant number.    
 
Quantitative phase  
Participants were recruited via BritPACT and the rheumatology members of the Group for 
Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).  The link was sent 
to approximately 510 clinicians internationally.  The online survey was open for four weeks 
and one reminder email was sent one week after the survey opened.  All responses were 
anonymous.  The data were analysed using descriptive statistics. 
 
Results  
Interviews and focus group 
Of the 80 who were invited to participate, ten consented to be interviewed; eight 
rheumatology consultants, one physiotherapist and one nurse specialist. Their time working 
in rheumatology ranged from 5-26 years, with one consultant delivering PsA-specific clinics. 
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Interviews lasted between 25-35 minutes.  The focus group included seven rheumatology 
consultants and two specialist registrars. Their time working in rheumatology ranged from 3-
22 years, with three clinicians delivering PsA-specific clinics. The focus group lasted for 102 
minutes. Following review of the interview and focus group data, authors ED, JT and LC 
identified an overarching theme of „Complexity‟, which incorporated three themes of „PsA 
versus RA‟, „Measurement‟, and „Resources‟. An underpinning theme of „Changes to current 
practice‟ captured the tension between themes of „Reluctance due to organisational factors‟ 
and „Local champions driving change‟ (see Figure 1).  
 
Complexity 
T2T in PsA was perceived as a complex process, including (i) the disease itself and its 
comparison to RA, (ii) the measurement challenges of T2T, and (iii) the resources needed to 
support implementation.  
 
 PsA versus RA 
Participants often compared PsA management to RA, where T2T is a more familiar 
approach, more adequately resourced, and more widely implemented.  
“all the resources have gone into RA pathways” [INT 05] 
 
Some participants thought that T2T in PsA is “not adequately evidence based and therefore 
no publicity and therefore low on the training profile” [INT 06]. In addition, PsA can be 
complex to manage clinically, making agreement on targets more of a challenge than in RA.   
“psoriatic arthritis is a complex disease, it’s much more complex than rheumatoid arthritis 
or ankylosing spondylitis” [FG 01] 
 
 Measurement: what, how and by whom?  
T2T requires treatment regimens to reach and maintain explicitly specified and sequentially 
measured goals. Participants discussed the complexity of developing protocols and 
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guidelines setting out these targets, with a view that “you don’t necessarily have to follow a 
guideline to treat a patient well” [INT 06]. Challenges included reaching consensus on what 
to measure, which instruments to use, how often measurement should happen, who would 
collect the data, and how it would be stored and accessed. Participants‟ views were shaped 
by what could be feasibly achieved within time-limited clinics. 
“if I am going to engage in T2T for my PsA patients, the questions are what assessments 
need to be completed and how do we store these? They have to be relevant to our care 
and accessible to those that need them, then we need to engage the IT department” [INT 
08] 
 
Participants discussed the need for training in measurement and assessment and concerns 
about being too prescriptive and losing sight of patient preferences for treatment.  
 “it’s not a fair perception of treat to target, but it’s almost tick box medicine if you haven’t 
hit this number, therefore we’re are going to change you to this … I want to ensure we’re 
still thinking about the patients” [INT 02] 
 
 Resources: team and organisational level support 
Participants identified a range of resource requirements spanning team needs (e.g. nursing 
support and registrar training) and organisational issues (e.g. length of appointments and IT 
support with database systems).  
“this [T2T] does not depend on the individual, it depends on the team and in 
particular the consultant that runs this clinic” [INT 03] 
 
One challenge was managing patients with PsA in a general rheumatology clinic, rather than 
a dedicated PsA clinic.  
“if you are doing a general clinic and you have a very general mishmash of patients, it’s 
just not pragmatic, it’s not practical to be doing lots of these activity assessments” [FG 
04] 
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Changes to current practice  
Underpinning the overarching theme of complexity is the theme of changing clinical practice. 
There was a tension between a reluctance to change, often attributed to organisational 
factors, and motivation to change, often due to individual determination to implement new 
ways of working.  
 
 Reluctance due to organisational factors  
Participants described the pressures of providing treatment in the current healthcare system, 
with limited time and staff resources. They identified the need to address other issues such 
as appointment waiting times before introducing an approach that might require intensive 
monitoring.  
“we are still struggling with our follow up appointments, particularly at the beginning 
when it’s important” [INT 01] 
 
However, participants identified two system-level factors that could facilitate change: the use 
of external mandates, tariffs or funding; and being able to demonstrate cost-savings.  
“I thought it [T2T] worked, but based on health economics I thought it was hard to justify, 
but with biosimilars getting cheaper, it’s a much easier argument now” [INT 02] 
 
 Local champions driving change  
In rheumatology teams implementing T2T, change was typically driven by individual 
clinicians with a specialist interest in PsA. They led on the development of PsA-specific care 
pathways, sought external information, training and support, pushed their local service 
forward, and championed a T2T approach.  
“I think it’s getting the right people and if you have a local lead champion somebody who 
will lead it and train the registrars and get people together in a clinic and do that then I 
think that’s probably the key” [FG 09] 
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Online survey 
Survey participants comprised 138 rheumatology consultants; 5 rheumatology 
trainee/fellows; 7 advanced practitioners; 1 dermatologist; 1 epidemiologist; and 1 
rheumatology practitioner (response rate approx. 30%). Time working in rheumatology 
ranged from 1-50 years (median 16; mean 18.5). Participants giving their country of practice 
were based in UK (33), Europe (37), North America (21), South America (25), Asia-Pacific 
(19), and other (7).  
 
The first survey section asked about opinions on T2T and highlighted some differences.  
While there was moderate support for the opinion that “PsA is a complex variable disease 
that is difficult to assess clinically within a T2T approach”, with 54% of participants strongly 
agreeing/agreeing, 36% of participants strongly disagreed or disagreed with this statement. 
Similar divergence was seen with the question “Following a T2T approach is not sufficiently 
flexible to tailor treatment for patients as individuals”, with 40% of participants strongly 
agreeing/agreeing and 44% of patients strongly disagreeing/ disagreeing.   
 
However, many participants supported the potential benefit of a T2T approach.  Only 15% of 
participants strongly agreed/agreed with “I don’t believe that a T2T approach will improve 
outcomes for my patients above my usual clinical care” and only 20% strongly 
agreed/agreed that “In my service, I do not think it is a priority to implement a T2T approach 
at present”. 
 
Responding to practical factors (five statements) about T2T implementation, just over half 
the participants (54.5%) thought that limited clinic appointment time was an important/very 
important factor in the difficulty of collecting outcome data. In response to the statement 
about the difficulty of collecting outcome data in mixed rheumatology clinics, just over 35% of 
participants reported that this was important/very important, compared to just over 49% who 
14 
 
reported that it was unimportant/very unimportant. Fewer than 18% of participants rated a 
lack of training in measuring outcomes in arthritis and enthesitis as important/very important 
for adopting a T2T approach. However, this figure increased to almost 35% for assessing 
skin disease.  
 
The final section asked about enabling factors (14 statements) to support T2T. The top ten 
enabling factors, rated as important/very important (Figure 2), included: “A protocol to 
support the implementation of T2T to use in my/my team’s clinics” (86.4%); “A member of 
my local team to lead on T2T implementation” (80.9%); “Support for me/my team in clinic to 
measure the outcomes needed to implement T2T” (83.3%); and “Training for me/my team 
about implementing T2T and the evidence for this approach” (69.8%). The importance of 
regular audit with feedback, specialist PsA clinics, and a web-based electronic database 
linked to hospital/national IT systems were also identified as enablers. 
 
Discussion: 
Currently, it is not common practice in the UK or internationally to use a T2T approach in 
PsA despite evidence of clinical effectiveness. Identification of barriers and enablers is key 
to understanding why uptake is low and for informing the design of an implementation 
study.18 Our qualitative data identified barriers that included the clinical complexity of PsA, a 
preference for clinical autonomy, the lack of available protocols, treatment of PsA in general 
clinics, and perceptions about insufficient reason to change. Enablers included clinical 
leadership, the provision of team training in PsA and its measurement, the availability of 
nurse support in clinics, setting up IT systems and dedicated databases and external 
incentives and/or requirements. Alongside organisational factors, physician beliefs are a key 
determinant of change. Evidence shows that clinical champions are important positive 
influences in healthcare innovation, from initiation and development through to 
implementation21. Overall, the survey data supported the qualitative findings, although there 
were some discrepancies. While the qualitative findings highlighted the challenge of 
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collecting outcomes when PsA patients attend general rheumatology clinics, this was not 
perceived to be an issue for most survey participants. A surprising survey finding was that a 
lack of training in outcome measures for “I/my team” was not identified as a significant 
barrier influencing adoption of T2T in participants‟ own clinical settings (section 2: practical 
factors), but provision of training for “me/my team” was identified as a key enabler (section 3: 
enabling factors). One reason for this could be that while participants were confident about 
their own knowledge, they were aware of other team members who would benefit from 
training. This would fit with the qualitative data on the importance of team support, especially 
for nurses and registrars.  
Many factors determine whether research evidence becomes established in practice. 
Unsurprisingly, systematic reviews have found that multifaceted implementation strategies 
are more effective than simple approaches.22-24. The fit between the intervention being 
implemented and the context in which it will be embedded is critical. Consideration must be 
given to the external context (including policies, incentivisation structures and dominant 
paradigms); organisational factors (including culture, available resources, integration with 
existing processes and skill mix); and individual factors (including professional role, and 
underlying philosophy of care).24 Several theoretical frameworks exist to inform 
implementation strategies, including behaviour change techniques and normalisation 
process theory.25 26 The current study findings will be used in combination with theoretical 
frameworks to inform an implementation strategy for T2T in PsA.  
 
Strengths and limitations: 
A strength of the current study is that participants were based in clinical practice, working in 
a range of settings and countries with different populations. Data were provided by a broad 
sample using different methods of collection. The interviews generated detailed evidence on 
views and experiences of T2T in PsA and the focus group provided an opportunity for a new 
sample of clinicians to debate this evidence. These qualitative findings were then put to a 
wider, international sample, which provided further confirmation of the key issues. The 
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consensus on the range of factors that need to be addressed to support implementation 
highlights the potential for international collaboration in this area. However, it is also 
important that shared models of implementation are flexible enough to adapt to cultural 
differences, such as spheres of influence and motivations to change practice, and respond 
to differences between health systems. Although current findings are based on data from 
many clinicians, participants were likely to have an interest in the care of PsA, which might 
have biased the findings. Therefore, their views might not be transferable or relevant to other 
UK rheumatology clinicians.  Another limitation is a low level of input from other 
rheumatology professions such as nurses, and from other stakeholders who shape service 
provision, such as commissioners.   
 
Implementation of a T2T approach in PsA will require an integrated approach that addresses 
the support, training and resource needs of individual clinicians, rheumatology teams, local 
IT systems, and service providers, and aligns with their current priorities, to maximise 
success.   
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Table 1: topic guide for interviews 
 
Context: clinical workload & care 
pathways  
 Number of clinics, patient numbers 
 Any clinics specific to PsA  
 Length of consultation  
 Patient waiting times between 
diagnosis and follow-up; from 
follow-up to starting meds; 
involvement of team members 
Views and experiences of Treat to 
Target (T2T) for psoriatic arthritis 
(PsA) 
 Your definition of T2T in PsA 
 What‟s measured and why? 
 How is it recorded?  
 Variation across the team 
Influences (individual and team)  Guidelines/pathways/protocols 
 Changes that could be made 
Enablers   What helps/encourages T2T 
Barriers  Challenges, difficulties  
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Table 2: topic guide for focus group (based on interview findings) 
 
The variation in definition and 
interpretation of T2T 
 
 Discuss remission and MDA  
 Explore formal assessment 
and measurement 
 
The variation in guidelines, protocols, 
and pathways 
 
 Explore available protocols in 
place currently  
 Explore meeting individual 
patient needs in T2T 
 Explore clinical autonomy in 
T2T 
 
Barriers to implementation 
 
 Discuss resources and time 
(currently) and requirements 
for T2T (ideally) 
 Discuss the role of external 
incentives and/or 
requirements 
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Figure 1 – Overarching themes around implementation of T2T in PsA as identified by 
qualitative interviews and focus group  
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Figure 2 – Top ten enabling factors to support T2T implementation in PsA as identified in the 
quantitative survey. 
 
 
